IL6 and cancer: Additionally, a study by Chang et al. suggests that measuring the serum levels of interleukin-6, alongside interleukin-1β and tumor necrosis factor α can be used to monitor cancer progression, as the proinflammatory cytokines are expressed more intensely in later stages of disease [122].